Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The Company’s SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The Company’s ZIMHI (naloxone) Injection product is approved for the treatment of opioid overdose. Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway.

Corporate Information

Adamis Pharmaceuticals Corporation
11682 El Camino Real, Suite # 300
San Diego, CA 92130
Phone: 858-997-2400
  Investor Relations:
Phone: 858-412-7951
Email: IR@adamispharma.com
Transfer Agent:
American Stock Transfer & Trust Company (AST)
6201 North 15th Avenue
Brooklyn, NY 11219
Jennifer Kane, Relationship Manager
Agent Phone: 602-759-5510
Agent Email: JKane@astfinancial.com
Team Email: Admin12@astfinancial.com
  Independent Auditor:
Mayer Hoffman McCann P.C.

Weintraub Tobin Chediak Coleman Grodin

Forward-Looking Statement
This website includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts, but are based on current expectations, assumptions, estimates and beliefs about our company and our industry. These statements are often, but not always, made through the use of word or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," and "would." Statements throughout this website concerning future events depend on several factors beyond the company's control, including receipt of adequate funding to support these activities. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, one or more of which may cause our actual results to be materially different from the forward-looking statements contained throughout this website.

Forward-looking statements contained on this website may include, but are not limited to, statements about our product candidates, research and development, strategies, objectives regulatory matters, markets, and future performance, future financial and operating results, the company's ability to obtain adequate funding to support its operations, the company's beliefs concerning the safety and effectiveness of its compounds and drug product candidates, the expected timing and outcome of future clinical trials of the company's product candidates, the expected timing and outcome of submissions to the FDA or other regulatory agencies for approvals to conduct clinical trials or for marketing approvals for our products, future revenues from sales of products, assuming that they are developed and approved for marketing by the FDA and other regulatory authorities, the current or future market sizes for the company's products, the extent of customer demand for the company's products, and the intellectual property protection that may be afforded by any patents or patent applications relating to the company's products, product candidates and technologies. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: Adamis' inability to obtain required funding, which could delay or prevent research, development and commercialization of its products; unexpected or adverse outcomes or developments at the FDA or other regulatory agencies; the impact of legislation that could affect the pharmaceutical industry; future clinical trials may not demonstrate the safety or effectiveness of its product candidates; market demand for Adamis' products may be materially different from expectations; patents and intellectual property may not be effective to protect Adamis' rights in its products or prevent other from developing competing products, or third parties may have patents or intellectual property that restrict Adamis' ability to commercialize and sell products; and Adamis' exposure to litigation and unexpected outcomes in litigation. Additional risks not known to Adamis or that Adamis believes are immaterial may also adversely affect its business, operating results and financial condition.

A more complete description of these and other risks and uncertainties that could cause actual results and events to differ materially from the outcomes anticipated by forward-looking statements is set forth under the caption "Risk Factors" contained in our annual report on Form 10-K (Part I, Item 1A) and in other reports Adamis files with the with the Securities and Exchange Commission (SEC), which are available at the SEC's Internet site (www.sec.gov). Adamis strongly urges you to read and consider each of those factors when evaluating the forward-looking statements.

No Duty to Update
The company assumes no duty to update the information contained in this website to reflect subsequent developments or to update any forward-looking statement contained in the website, except as may be required by applicable law.

Data Provided by Refinitiv. Minimum 15 minutes delayed.